Moleculin Biotech, Inc. (MBRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Moleculin Biotech reported revenue of $0. Net income was -$33.6M. Operating activities generated -$22.7M of cash. At fiscal year end, Moleculin Biotech held $22.1M in total assets against $7.1M in total liabilities, including $8.9M of cash and equivalents.
Open the full interactive Moleculin Biotech financials → Quarterly statements, key ratios, valuation history and price charts.
Moleculin Biotech Key Stats
| Share Price | $0.44 |
|---|---|
| Market Cap | $2.5M |
| 52-Week Range | $0.38 – $13.00 |
| Shares Outstanding | 5.7 million (basic, 2026 Q2) |
Moleculin Biotech Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$19.7M | -$23.0M | -$30.6M | -$29.6M | -$26.6M | -$25.1M |
| Pre-Tax Income | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$21.8M | -$33.6M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$21.8M | -$33.6M |
| Diluted EPS | -$660.00 | -$221.25 | — | — | — | — |
Moleculin Biotech Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$25.4M | $5.9M | -$12.8M | -$7.6M |
Moleculin Biotech Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.2M | $70.9M | $43.1M | $23.6M | $4.3M | $8.9M |
| Current Assets | $17.2M | $72.5M | $45.6M | $26.3M | $5.2M | $9.7M |
| Total Assets | $29.0M | $84.1M | $57.4M | $38.2M | $16.9M | $22.1M |
| Current Liabilities | $2.9M | $3.6M | $4.8M | $6.8M | $5.4M | $6.9M |
| Total Liabilities | $11.3M | $5.1M | $5.2M | $12.1M | $10.9M | $7.1M |
| Shareholders' Equity | $17.8M | $79.0M | $52.2M | $26.1M | $6.0M | $15.0M |
Moleculin Biotech Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$17.8M | -$19.0M | -$27.6M | -$24.1M | -$23.9M | -$22.7M |
| Cash From Investing | -$374,000 | -$19,000 | -$67,000 | -$124,000 | -$13,000 | $0 |
| Cash From Financing | $22.5M | $74.7M | -$23,000 | $4.7M | $4.6M | $27.3M |
| Free Cash Flow | -$18.2M | -$19.0M | -$27.7M | -$24.2M | -$23.9M | -$22.7M |
Figures from Moleculin Biotech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Moleculin Biotech financials page for every line item.
Moleculin Biotech Company Profile
| Ticker | MBRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Houston, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001659617 |
Frequently Asked Questions
What was Moleculin Biotech's revenue in fiscal 2025?
Moleculin Biotech (MBRX) reported revenue of $0 for fiscal 2025.
What is Moleculin Biotech's annual revenue history?
Moleculin Biotech's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Moleculin Biotech's net income in fiscal 2025?
Moleculin Biotech reported net income of -$33.6M for fiscal 2025.
What was Moleculin Biotech's revenue last quarter?
In its most recent reported quarter (2026 Q2), Moleculin Biotech reported revenue of $0.
How many shares of Moleculin Biotech are outstanding?
Moleculin Biotech reported a weighted average of 5.7 million basic shares outstanding in 2026 Q2.
What is Moleculin Biotech's market cap?
Based on its latest closing price, Moleculin Biotech (MBRX) has a market capitalization of about $2.5M.
When does Moleculin Biotech's fiscal year end?
Moleculin Biotech's fiscal year end, as registered with the SEC, is December 31.
Where is Moleculin Biotech headquartered?
Moleculin Biotech lists its business address in Houston, Texas in its SEC filings.